Anakinra dosing study for preterm infants
Treatments studied
Part of Genetic & congenital, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests different doses and ways of giving a medicine called anakinra to preterm babies. It aims to find the safest and most effective dose to help reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby was born between 24 weeks and 28 weeks plus 6 days of pregnancy.
- Your baby does not have a known genetic syndrome.
- Your baby does not have severe heart problems.
- Your baby did not have a stroke before birth.
- Your baby does not have a hole in the diaphragm (congenital diaphragmatic hernia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called anakinra to see if it can prevent severe drops in blood sugar after eating in people who have had their stomach removed. It is designed for one person, so results may not apply to everyone.
This is an early-stage study testing a new injectable treatment called KT502 for people with moderate-to-severe rheumatoid arthritis (RA) that hasn't responded well to standard treatments. The study will check if the medication is safe and how the body responds to it.
This study tests a medicine called anakinra that may reduce heart swelling in children with a severe heart condition called acute myocarditis. It might help their heart recover faster while they are in the intensive care unit.
This study tests whether a drug called anakinra, given as a shot, can help treat moderate asthma attacks right when they happen, reducing the need for other rescue treatments. It may help people whose asthma is not well controlled and who have needed steroids in the past year.
This study tests whether anakinra, a medicine that calms inflammation, is just as good as the standard treatment for Kawasaki disease in children. The goal is to reduce fever and prevent heart problems.
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
Hear when a new Premature Infants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.